SALOFALK Gastro-resistant tablet Ref.[50880] Active ingredients: Mesalazine

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2023  Publisher: Dr. Falk Pharma GmbH, Leinenweberstr. 5, 79108 Freiburg, Germany, Tel.: +49 (0)761 1514-0, Fax: +49 (0)761 1514-321, E-mail: zentrale@drfalkpharma.de, www.drfalkpharma.de

4.1. Therapeutic indications

For the treatment of acute episodes of mild to moderate ulcerative colitis.

4.2. Posology and method of administration

Posology

Adults

The recommended daily dose for the treatment of acute episodes of mild to moderate ulcerative colitis is one Salofalk 1g tablet three times a day (morning, midday and evening, equivalent to 3g of mesalazine daily).

Paediatric population

There is only limited documentation for an effect in children (age 6-18 years).

Children 6 years of age and older

The dose should be determined individually, starting with 30-50 mg/kg/day in divided doses.

Maximum dose: 75mg/kg/day. The total dose should not exceed the maximum adult dose.

It is generally recommended that half the adult dose may be given to children up to a body weight of 40kg and the normal adult dose to those above 40kg.

In children below 40kg, it appears preferable to use mesalazine preparations of lower strengths (e.g., Salofalk 500mg gastro-resistant tablets or Salofalk 500mg gastro-resistant prolonged-release granules).

Method of administration

Salofalk 1g tablets should be taken 1 hour before meals. They should be swallowed whole, not chewed and taken with plenty of fluid.

Therapy with Salofalk 1g tablets should be administered regularly and consistently in order to achieve the desired therapeutic effect.

Duration of treatment

The duration of use is determined by the physician. Induction of remission is usually achieved within 8 weeks.

Note: The standard treatment of the maintenance of remission is 500mg mesalazine three times daily. For this indication tablets containing 500mg mesalazine (e.g., Salofalk 500mg gastro-resistant tablets) are available.

4.9. Overdose

There are rare data on overdose (e.g. intended suicide with high oral doses of mesalazine), which do not indicate renal or hepatic toxicity. There is no specific antidote and treatment is symptomatic and supportive.

6.3. Shelf life

3 years.

6.4. Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5. Nature and contents of container

Blister: PVC/PVDC (orange-transparent)/aluminium blister foil

Package sizes: Blister packs with 20, 50, 60, 90,100 and 150 Salofalk 1g tablets.

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.